Global Peptide Therapeutics Market to Reach $56.3 Billion by 2030
The global market for Peptide Therapeutics estimated at US$40.2 Billion in the year 2022, is projected to reach a revised size of US$56.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2022-2030. Innovative, one of the segments analyzed in the report, is projected to record 2.8% CAGR and reach US$29.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Generic segment is readjusted to a revised 6.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $10.9 Billion, While China is Forecast to Grow at 7.4% CAGR
The Peptide Therapeutics market in the U.S. is estimated at US$10.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$12.4 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.6% and 4.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.Select Competitors (Total 33 Featured) -
- AbbVie, Inc.
- Advanced Accelerator Applications SA
- Akashi Therapeutics, Inc.
- Amgen, Inc.
- Anthera Pharmaceuticals, Inc.
- AstraZeneca PLC
- Bachem AG
- Bristol-Myers Squibb Company
- Cardiorentis AG
- Corden Pharma International GmbH
- Debiopharm Group
- Derma Sciences, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Hanmi Pharmaceutical Co., Ltd.
- Insmed, Inc.
- Ipsen Group
- Johnson & Johnson
- Lonza Group AG
- Mallinckrodt PLC
- Merck & Co., Inc.
- MolMed S.p.A.
- Novartis AG
- Novo Nordisk A/S
- Nymox Pharmaceutical Corporation
- PAR Pharmaceutical Companies, Inc.
- PeptiDream Inc.
- Pfizer, Inc.
- PolyPeptide Group
- Radius Health, Inc.
- Repligen Corporation
- Sanofi SA
- SciClone Pharmaceuticals Holding Limited.
- Shire PLC
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- The Medicines Company
- X-GEN Pharmaceuticals, Inc.
- Zealand Pharma A/S
- Zydus Cadila
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Advanced Accelerator Applications SA
- Akashi Therapeutics, Inc.
- Amgen, Inc.
- Anthera Pharmaceuticals, Inc.
- AstraZeneca PLC
- Bachem AG
- Bristol-Myers Squibb Company
- Cardiorentis AG
- Corden Pharma International GmbH
- Debiopharm Group
- Derma Sciences, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Hanmi Pharmaceutical Co., Ltd.
- Insmed, Inc.
- Ipsen Group
- Johnson & Johnson
- Lonza Group AG
- Mallinckrodt PLC
- Merck & Co., Inc.
- MolMed S.p.A.
- Novartis AG
- Novo Nordisk A/S
- Nymox Pharmaceutical Corporation
- PAR Pharmaceutical Companies, Inc.
- PeptiDream Inc.
- Pfizer, Inc.
- PolyPeptide Group
- Radius Health, Inc.
- Repligen Corporation
- Sanofi SA
- SciClone Pharmaceuticals Holding Limited.
- Shire PLC
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- The Medicines Company
- X-GEN Pharmaceuticals, Inc.
- Zealand Pharma A/S
- Zydus Cadila
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 192 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 40.2 Billion |
Forecasted Market Value ( USD | $ 56.3 Billion |
Compound Annual Growth Rate | 4.3% |
Regions Covered | Global |